Search Results

Volta Medical today announced presentations to be made at the Heart Rhythm Society 2024 meeting in Boston, May 16 to 19. In-person attendance and live online participation in a hybrid format will be available.

Data demonstrates improvement in cardiac function and reductions in cardiac hypertrophy, remodeling, inflammation, and cell death - key underlying mechanisms in heart failure

Boston Pharma’s once-monthly injection efimosfermin alfa offers a convenient dosing option for MASH patients while also achieving promising rates of fibrosis and MASH improvement, according to a Phase II readout.

Stereotaxis announced that it has been invited to present at HRS Africa Summit 2024, scheduled to take place during Heart Rhythm Society Scientific Sessions this week in Boston, Massachusetts.

Integer Holdings Corporation will join medtech industry leaders around the world in exhibiting at Heart Rhythm 2024, a Heart Rhythm Society educational event and exhibition in Boston from May 16 – 19, 2024.

Daxor Corporation today announces it will be exhibiting at the Technology and Heart Failure Therapeutics Conference (THT), which brings together the world’s leading experts in heart failure innovations at the Westin Boston Seaport in Boston, Massachusetts March 4-6, 2024.

Milestone® Pharmaceuticals Inc. announced upcoming data presentations on etripamil at ISPOR 2024 being held in Atlanta, GA on May 5-8, 2024, the 2024 Stanford BioDesign Arrhythmia Technologies Retreat in Boston, MA, on May 15, 2024, and the Annual meeting of the Heart Rhythm Society, Heart Rhythm 2024, in Boston, MA on May 16-19, 2024.

Eli Lilly’s new research and development facility in Boston’s Seaport district will focus on DNA- and RNA-based therapies, as well as other priority areas such as diabetes and obesity.